Lab Notes: Chimeron Bio names new CEO; Amicus Therapeutics gets positive opinion for rare disease therapy
This week's Philadelphia-area life sciences industry news includes a biotechnology firm naming a new CEO, positive study results on an experimental cancer therapy for another, progress on a potential treatment for a rare disorder for a third, and more.
Here is the roundup:
The Philadelphia biotechnology company developing self-amplifying RNA vaccines and therapeutics has named Kevin Heyeck as its new CEO.
He succeeds former chief executive Jolly Mazumdar, who departed the post earlier this month …
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: John George Source Type: news
More News: American Health | Biotechnology | Cancer | Cancer & Oncology | Cancer Therapy | Cancer Vaccines | Health Management | Rare Diseases | Study | Vaccines